Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Safety,Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers.

Next Previous
Search
Trial Profile

Evaluation of Safety,Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilofabicin (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections; Vancomycin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions
  • Sponsors CrystalGenomics

    • Most Recent Events

    • 10 May 2010 According to a CrystalGenomics media release, the company has succesfully completed the single ascending dose Phase I clinical trial for CG400549.
    • 13 Mar 2010 Actual initiation date (Oct 2009), planned no of patients [18], official title added as reported by ClinicalTrials.gov.
    • 13 Mar 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top